An update on combination therapies for multiple sclerosis: where are we now?

References

• Comi G, Radaelli M, Soelberg Sorensen P. Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet. 2017;389(10076):1347–1356. doi:10.1016/S0140-6736(16)32388-1
   PubMed Web of Science ®Google Scholar
• Duquette P, Girard M, Despault L, et al. Interferon beta-1B is effective in relapsing-remitting multiple-sclerosis - clinical-results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):655–661.
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The MUltiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39(3):285–294. doi: 10.1002/ana.410390304
   PubMed Web of Science ®Google Scholar
• PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139):1498–1504. doi: 10.1016/S0140-6736(98)03334-0
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The copolymer 1 multiple sclerosis study group [see comments]. Neurology. 1995;45(7):1268–1276.
   PubMed Web of Science ®Google Scholar
• Yong VW, Chabot S, Stuve O, et al. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology. 1998;51(3):682–689. doi:10.1212/WNL.51.3.682
   PubMed Web of Science ®Google Scholar
• Gran B, Tranquill LR, Chen M, et al. Mechanisms of immunomodulation by glatiramer acetate. Neurology. 2000;55(11):1704–1714. doi: 10.1212/WNL.55.11.1704
   PubMed Web of Science ®Google Scholar
• Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med. 1983;308(4):173–180.
   PubMed Web of Science ®Google Scholar
• Patzold U, Pocklington P. Azathioprine in multiple sclerosis–a 3 year controlled study of its effectiveness. J Neurol. 1980;223(2):97–117. doi:10.1007/BF00313173
   PubMed Web of Science ®Google Scholar
• Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360(9350):2018–2025. doi: 10.1016/S0140-6736(02)12023-X
   PubMed Web of Science ®Google Scholar
• Martinelli V, Radaelli M, Straffi L, et al. Mitoxantrone: benefits and risks in multiple sclerosis patients. Neurol Sci. 2009;Suppl 30(S2):S167–S170. doi: 10.1007/s10072-009-0142-7
   Google Scholar
• Miller AE. Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience. Ther Adv Neurol Disord. 2017;10(12):381–396. doi:10.1177/1756285617722500
   PubMed Web of Science ®Google Scholar
• Sorensen PS. New management algorithms in multiple sclerosis. Curr Opin Neurol. 2014;27(3):246–259. doi:10.1097/WCO.0000000000000096
   PubMed Web of Science ®Google Scholar
• Najjar E, Staun-Ram E, Volkowich A, et al. Dimethyl fumarate promotes B cell-mediated anti-inflammatory cytokine profile in B and T cells, and inhibits immune cell migration in patients with MS. J Neuroimmunol. 2020;343:577230. doi:10.1016/j.jneuroim.2020.577230
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910. doi: 10.1056/NEJMoa044397
   PubMed Web of Science ®Google Scholar
• Sellebjerg F, Cadavid D, Steiner D, et al. Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis. Ther Adv Neurol Disord. 2016;9(1):31–43. doi:10.1177/1756285615615257
   PubMed Web of Science ®Google Scholar
• Cohen JA, Chun J. Mechanisms of fingolimod’s efficacy and adverse effects in multiple sclerosis. Ann Neurol. 2011;69(5):759–777. doi:10.1002/ana.22426
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401. doi: 10.1056/NEJMoa0909494
   PubMed Web of Science ®Google Scholar
• Comi G, Kappos L, Selmaj KW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019;18(11):1009–1020. doi: 10.1016/S1474-4422(19)30239-X
   PubMed Web of Science ®Google Scholar
• Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263–1273. doi: 10.1016/S0140-6736(18)30475-6
   PubMed Web of Science ®Google Scholar
• Kappos L, Fox RJ, Burcklen M, et al. Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial. JAMA Neurol. 2021;78(5):558–567. doi: 10.1001/jamaneurol.2021.0405
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416–426. doi: 10.1056/NEJMoa0902533
   PubMed Web of Science ®Google Scholar
• Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol. 2011;34(1):28–35. doi:10.1097/WNF.0b013e318204cd90
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017;376(3):221–234. doi: 10.1056/NEJMoa1601277
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, et al. B-Cell depletion with Rituximab in relapsing–remitting multiple sclerosis. N Engl J Med. 2008;358(7):676–688. doi: 10.1056/NEJMoa0706383
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546–557. doi: 10.1056/NEJMoa1917246
   PubMed Web of Science ®Google Scholar
• Sellebjerg F, Blinkenberg M, Sorensen PS. Anti-CD20 monoclonal antibodies for relapsing and progressive multiple sclerosis. CNS Drugs. 2020;34(3):269–280. doi:10.1007/s40263-020-00704-w
   PubMed Web of Science ®Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829–1839. doi: 10.1016/S0140-6736(12)61768-1
   PubMed Web of Science ®Google Scholar
• Hartung HP, Aktas O, Boyko AN. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. Mult Scler. 2015;21(1):22–34. doi:10.1177/1352458514549398
   PubMed Web of Science ®Google Scholar
• Stuart WH. Combination therapy for the treatment of multiple sclerosis: challenges and opportunities. Curr Med Res Opin. 2007;23(6):1199–1208. doi:10.1185/030079907X187838
   PubMed Web of Science ®Google Scholar
• Rutherford GW, Sangani PR, Kennedy GE, Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection. Cochrane Database Syst Rev. 2003;4: CD002037. doi:10.1002/14651858.CD002037.
   Google Scholar
• Greco A, Safi D, Swami U, et al. Efficacy and adverse events in metastatic melanoma patients treated with combination BRAF plus MEK inhibitors versus BRAF inhibitors: a systematic review. Cancers (Basel). 2019;11(12):1950.
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26–37. doi: 10.1002/art.21519
   PubMed Web of Science ®Google Scholar
• Lublin FD, Cofield SS, Cutter GR, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol. 2013;73(3):327–340. doi: 10.1002/ana.23863
   PubMed Web of Science ®Google Scholar
• Lublin FD, Cofield SS, Cutter GR, et al. Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: efficacy and safety results up to 7 years. Multi Sclerosis Relat Disord. 2017;18:95–102. doi: 10.1016/j.msard.2017.09.012
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC. Combination therapy for treatment of multiple sclerosis. Ann Neurol. 1998;44(1):7–9. doi:10.1002/ana.410440106
   PubMed Web of Science ®Google Scholar
• Ozakbas S, Cinar BP, Kosehasanogullari G, et al. Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: a multicentre, single-blind, prospective trial. Clin Neurol Neurosur. 2017;160:69–72. doi:10.1016/j.clineuro.2017.06.016
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Mellgren SI, Svenningsson A, et al. Nordic trial of oral methylprednisolone as add-on therapy to interferon beta-1a for treatment of relapsing-remitting multiple sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol. 2009;8(6):519–529. doi: 10.1016/S1474-4422(09)70085-7
   PubMed Web of Science ®Google Scholar
• Pozzilli C, Antonini G, Bagnato F, et al. Monthly corticosteroids decrease neutralizing antibodies to IFNβ1b: a randomized trial in multiple sclerosis. J Neurol. 2002;249(1):50–56. doi: 10.1007/PL00007847
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Haas J, Sellebjerg F, et al. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology. 2004;63(11):2028–2033. doi:10.1212/01.WNL.0000145798.61383.39
   PubMed Web of Science ®Google Scholar
• Green AJ, Gelfand JM, Cree BA, et al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet. 2017;390(10111):2481–2489. doi: 10.1016/S0140-6736(17)32346-2
   PubMed Web of Science ®Google Scholar
• Le Page E, Edan G. Induction or escalation therapy for patients with multiple sclerosis? Rev Neurol (Paris). 2018;174(6):449–457. doi:10.1016/j.neurol.2018.04.004
   PubMed Web of Science ®Google Scholar
• Comi G. Induction vs. escalating therapy in multiple sclerosis: practical implications. Neurol Sci. 2008;29 Suppl 2:S253–255. doi:10.1007/s10072-008-0954-x
   PubMed Web of Science ®Google Scholar
• Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry. 1997;62(2):112–118. doi: 10.1136/jnnp.62.2.112
   PubMed Web of Science ®Google Scholar
• Vollmer T, Panitch H, Bar-Or A, et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler. 2008;14(5):663–670. doi: 10.1177/1352458507085759
   PubMed Web of Science ®Google Scholar
• Edan G, Comi G, Le PE, et al. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. J Neurol Neurosurg Psychiatry. 2011;82(12):1344–1350. doi: 10.1136/jnnp.2010.229724
   PubMed Web of Science ®Google Scholar
• Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911–923. doi: 10.1056/NEJMoa044396
   PubMed Web of Science ®Google Scholar
• Goodman AD, Rossman H, Bar-Or A, et al. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology. 2009;72(9):806–812. doi: 10.1212/01.wnl.0000343880.13764.69
   PubMed Web of Science ®Google Scholar
• Togha M, Karvigh SA, Nabavi M, et al. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Mult Scler. 2010;16(7):848–854. doi: 10.1177/1352458510369147
   PubMed Web of Science ®Google Scholar
• Lanzillo R, Orefice G, Quarantelli M, et al. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing— remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler. 2010;16(4):450–454. doi: 10.1177/1352458509358909
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Lycke J, Eralinna JP, et al. Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol. 2011;10(8):691–701. doi: 10.1016/S1474-4422(11)70144-2
   PubMed Web of Science ®Google Scholar
• Kamm CP, El-Koussy M, Humpert S, et al. Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial. J Neurol. 2012;259(11):2401–2413. doi: 10.1007/s00415-012-6513-7
   PubMed Web of Science ®Google Scholar
• Lanzillo R, Quarantelli M, Pozzilli C, et al. No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon beta1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study). Mult Scler. 2016;22(9):1163–1173. doi: 10.1177/1352458515611222
   PubMed Web of Science ®Google Scholar
• Metz LM, Li D, Traboulsee A, et al. Glatiramer acetate in combination with minocycline in patients with relapsing—remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial. Mult Scler. 2009;15(10):1183–1194.
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Sellebjerg F, Lycke J, et al. Minocycline added to subcutaneous interferon beta-1a in multiple sclerosis: randomized RECYCLINE study. Eur J Neurol. 2016;23(5):861–870. doi: 10.1111/ene.12953
   PubMed Web of Science ®Google Scholar
• Cohen JA, Imrey PB, Calabresi PA, et al. Results of the Avonex combination trial (ACT) in relapsing-remitting MS. Neurology. 2009;72(6):535–541. doi: 10.1212/01.wnl.0000341934.12142.74
   PubMed Web of Science ®Google Scholar
• Ravnborg M, Sorensen PS, Andersson M, et al. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol. 2010;9(7):672–680. doi: 10.1016/S1474-4422(10)70132-0
   PubMed Web of Science ®Google Scholar
• Havrdova E, Zivadinov R, Krasensky J, et al. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Mult Scler. 2009;15(8):965–976. doi: 10.1177/1352458509105229
   PubMedGoogle Scholar
• Voskuhl RR, Wang H, Wu TC, et al. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(1):35–46. doi: 10.1016/S1474-4422(15)00322-1
   PubMed Web of Science ®Google Scholar
• Khoury SJ, Healy BC, Kivisakk P, et al. A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. Arch Neurol. 2010;67(9):1055–1061. doi: 10.1001/archneurol.2010.222
   PubMedGoogle Scholar
• Kaiser CC, Shukla DK, Stebbins GT, et al. A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. J Neuroimmunol. 2009;211(1–2):124–130. doi: 10.1016/j.jneuroim.2009.04.011
   PubMed Web of Science ®Google Scholar
• Gonsette RE, Sindic C, D’Hooghe MB, et al. Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and interferon β in relapsing- remitting multiple sclerosis (ASIIMS) trial. Mult Scler. 2010;16(4):455–462. doi: 10.1177/1352458509360547
   PubMed Web of Science ®Google Scholar
• Munoz Garcia D, Midaglia L, Martinez Vilela J, et al. Associated Inosine to interferon: results of a clinical trial in multiple sclerosis. Acta Neurol Scand. 2015;131(6):405–410. doi: 10.1111/ane.12333
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 2012;18(2):143–152. doi: 10.1177/1352458511435105
   PubMed Web of Science ®Google Scholar
• Freedman MS, Wolinsky JS, Wamil B, et al. Teriflunomide added to interferon-beta in relapsing multiple sclerosis: a randomized phase II trial. Neurology. 2012;78(23):1877–1885. doi: 10.1212/WNL.0b013e318258f7d4
   PubMed Web of Science ®Google Scholar
• Ytterberg C, Johansson S, Andersson M, et al. Combination therapy with interferon-beta and glatiramer acetate in multiple sclerosis. Acta Neurol Scand. 2007;116(2):96–99. doi: 10.1111/j.1600-0404.2007.00801.x
   PubMed Web of Science ®Google Scholar
• Chataway J, Schuerer N, Alsanousi A, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet. 2014;383(9936):2213–2221.
   PubMed Web of Science ®Google Scholar
• Rudick RA, Pace A, Rani MR, et al. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology. 2009;72(23):1989–1993. doi: 10.1212/WNL.0b013e3181a92b96
   PubMed Web of Science ®Google Scholar
• Birnbaum G, Cree B, Altafullah I, et al. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology. 2008;71(18):1390–1395. doi: 10.1212/01.wnl.0000319698.40024.1c
   PubMed Web of Science ®Google Scholar
• Ghasami K, Faraji F, Fazeli M, et al. Interferon beta-1a and atorvastatin in the treatment of multiple sclerosis. Iran J Immunol. 2016;13(1):16–26.
   PubMed Web of Science ®Google Scholar
• Maier K, Merkler D, Gerber J, et al. Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation. Neurobiol Dis. 2007;25(3):514–525. doi: 10.1016/j.nbd.2006.10.022
   PubMed Web of Science ®Google Scholar
• Metz LM, DKB L, Traboulsee AL, et al. Trial of minocycline in a clinically isolated syndrome of multiple sclerosis. N Engl J Med. 2017;376(22):2122–2133. doi: 10.1056/NEJMoa1608889
   PubMed Web of Science ®Google Scholar
• Beck RW, Cleary PA, Anderson MMJ, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group [see comments]. N Engl J Med. 1992;326(9):581–588.
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing- remitting MS. Neurology. 2001;57(7):1239–1247. doi: 10.1212/WNL.57.7.1239
   PubMed Web of Science ®Google Scholar
• Smith DR, Weinstock-Guttman B, Cohen JA, et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. Mult Scler. 2005;11(5):573–582. doi: 10.1191/1352458505ms1210oa
   PubMed Web of Science ®Google Scholar
• Kalincik T, Horakova D, Dolezal O, et al. Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. Clin Neurol Neurosurg. 2012;114(7):940–946.
   PubMed Web of Science ®Google Scholar
• Milligan NM, Miller DH, Compston DA. A placebo-controlled trial of isoprinosine in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 1994;57(2):164–168. doi: 10.1136/jnnp.57.2.164
   PubMed Web of Science ®Google Scholar
• Amato MP, Derfuss T, Hemmer B, et al. Environmental modifiable risk factors for multiple sclerosis: report from the 2016 ECTRIMS focused workshop. Mult Scler. 2018;1352458516686847(5):590–603.
   Google Scholar
• Fitzgerald KC, Munger KL, Kochert K, et al. Association of vitamin D levels with multiple sclerosis activity and progression in patients receiving interferon beta-1b. JAMA Neurol. 2015;72(12):1458–1465. doi: 10.1001/jamaneurol.2015.2742
   PubMed Web of Science ®Google Scholar
• Müller T, Lohse L, Blodau A, et al. Vitamin D and Blood Parameters. Biomolecules. 2021 Jul 12;11(7):1017. doi: 10.3390/biom11071017
   PubMed Web of Science ®Google Scholar
• Soilu-Hanninen M, Aivo J, Lindstrom BM, et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(5):565–571. doi: 10.1136/jnnp-2011-301876
   PubMed Web of Science ®Google Scholar
• Shaygannejad V, Janghorbani M, Ashtari F, et al. Effects of adjunct low-dose vitamin d on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Mult Scler Int. 2012;2012:452541. doi: 10.1155/2012/452541
   PubMedGoogle Scholar
• Hupperts R, Smolders J, Vieth R, et al. Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon beta-1a. Neurology. 2019;93(20):e1906–e1916. doi: 10.1212/WNL.0000000000008445
   PubMed Web of Science ®Google Scholar
• Jagannath VA, Filippini G, Di Pietrantonj C, et al. Vitamin D for the management of multiple sclerosis. Cochrane Database Syst Rev. 2018;9(6):CD008422.
   PubMedGoogle Scholar
• Shaygannejad V, Janghorbani M, Savoj MR, et al. Effects of adjunct glucosamine sulfate on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized, placebo-controlled trial. Neurological res. 2010;32(9):981–985. doi:10.1179/016164110X12656393664964
   PubMed Web of Science ®Google Scholar
• Ramirez-Ramirez V, Macias-Islas MA, Ortiz GG, et al. Efficacy of fish oil on serum of TNF alpha, IL-1 beta, and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b. Oxid Med Cell Longev. 2013;2013:709493. doi: 10.1155/2013/709493
   PubMed Web of Science ®Google Scholar
• Torkildsen O, Wergeland S, Bakke S, et al. ω-3 fatty acid treatment in multiple sclerosis (OFAMS study). Arch Neurol. 2012;69(8). doi: 10.1001/archneurol.2012.283
   PubMedGoogle Scholar
• Lovera J, Ramos A, Devier D, et al. Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: phase I single group and phase II randomized placebo-controlled studies. J Neurol Sci. 2015;358(1–2):46–52. doi: 10.1016/j.jns.2015.08.006
   PubMed Web of Science ®Google Scholar
• Koulinska I, Riester K, Chalkias S, et al. Effect of bismuth subsalicylate on gastrointestinal tolerability in healthy volunteers receiving oral delayed-release dimethyl fumarate: PREVENT, a randomized, multicenter, double-blind, placebo-controlled study. Clin Ther. 2018;40(12):2021–2030.e1. doi:10.1016/j.clinthera.2018.10.013
   PubMed Web of Science ®Google Scholar
• Sorensen PS. Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis. CNS Drugs. 2022;36(6):569–589. doi:10.1007/s40263-022-00920-6
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Koch-Henriksen N, Ross C, et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology. 2005;65(1):33–39. doi:10.1212/01.WNL.0000166049.51502.6A
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet. 2003;362(9391):1184–1191. doi: 10.1016/S0140-6736(03)14541-2
   PubMed Web of Science ®Google Scholar
• Hesse D, Frederiksen JL, Koch-Henriksen N, et al. Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-β. Euro J Of Neurology. 2009;16(1):43–47. doi: 10.1111/j.1468-1331.2008.02336.x
   PubMed Web of Science ®Google Scholar
• Ravnborg M, Bendtzen K, Christensen O, et al. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis. Mult Scler. 2009;15(3):323–328. doi: 10.1177/1352458508099476
   PubMedGoogle Scholar
• Visser LH, Beekman R, Tijssen CC, et al. A randomized, double-blind, placebo-controlled pilot study of i.V. immune globulins in combination with i.V. methylprednisolone in the treatment of relapses in patients with MS. Mult Scler. 2004;10(1):89–91. doi: 10.1191/1352458504ms978sr
   PubMedGoogle Scholar
• Najmi Varzaneh F, Najmi Varzaneh F, Azimi AR, et al. Efficacy of combination therapy with erythropoietin and methylprednisolone in clinical recovery of severe relapse in multiple sclerosis. Acta Neurol Belg. 2014;114(4):273–278. doi:10.1007/s13760-014-0286-y
   PubMed Web of Science ®Google Scholar
• Borhani-Haghighi A, Ghodsi M, Razeghinejad MR, et al. Erythropoietin for acute multiple sclerosis in patients with optic neuritis as a first demyelination event. Neurosciences (Riyadh). 2012;17(2):151–155.
   PubMed Web of Science ®Google Scholar
• Mei F, Fancy SPJ, Shen YA, et al. Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Nature Med. 2014;20(8):954–960. doi: 10.1038/nm.3618
   PubMed Web of Science ®Google Scholar
• Moghaddasi M, Nabovvati M, Koushki A, et al. Randomized control trial of evaluation of Clemastine effects on visual evoked potential, nerve fiber layer and ganglion cell layer complex in patients with optic neuritis. Clin Neurol Neurosur. 2020;193:105741. doi: 10.1016/j.clineuro.2020.105741
   PubMed Web of Science ®Google Scholar
• Schwartzbach CJ, Grove RA, Brown R, et al. Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study. J Neurol. 2017;264(2):304–315. doi:10.1007/s00415-016-8341-7
   PubMed Web of Science ®Google Scholar
• Huang JK, Jarjour AA, Nait Oumesmar B, et al. Retinoid X receptor gamma signaling accelerates CNS remyelination. Nat Neurosci. 2011;14(1):45–53. doi: 10.1038/nn.2702
   PubMed Web of Science ®Google Scholar
• Brown JWL, Cunniffe NG, Prados F, et al. Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR one): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. Lancet Neurol. 2021;20(9):709–720. doi: 10.1016/S1474-4422(21)00179-4
   PubMed Web of Science ®Google Scholar
• Mi S, Pepinsky RB, Cadavid D. Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic. CNS Drugs. 2013;27(7):493–503. doi:10.1007/s40263-013-0068-8
   PubMed Web of Science ®Google Scholar
• Tran JQ, Rana J, Barkhof F, et al. Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol(r) Neuroimmunol Neuroinflammation. 2014;1(2):e18. doi: 10.1212/NXI.0000000000000018
   PubMedGoogle Scholar
• Cadavid D, Balcer L, Galetta S, et al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16(3):189–199. doi: 10.1016/S1474-4422(16)30377-5
   PubMed Web of Science ®Google Scholar
• Cadavid D, Mellion M, Hupperts R, et al. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019;18(9):845–856. doi: 10.1016/S1474-4422(19)30137-1
   PubMed Web of Science ®Google Scholar
• Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci. 2005;6(6):484–494. doi:10.1038/nrn1687
   PubMed Web of Science ®Google Scholar
• Cervellini I, Ghezzi P, Mengozzi M. Therapeutic efficacy of erythropoietin in experimental autoimmune encephalomyelitis in mice, a model of multiple sclerosis. Methods Mol Biol. 2013;982:163–173.
   PubMedGoogle Scholar
• Schreiber K, Magyari M, Sellebjerg F, et al. High-dose erythropoietin in patients with progressive multiple sclerosis: a randomized, placebo-controlled, phase 2 trial. Mult Scler. 2017;23(5):675–685. doi: 10.1177/1352458516661048
   PubMed Web of Science ®Google Scholar
• Lagreze WA, Kuchlin S, Ihorst G, et al. Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study. Lancet Neurol. 2021;20(12):991–1000. doi: 10.1016/S1474-4422(21)00322-7
   PubMed Web of Science ®Google Scholar
• Chan D, Binks S, Nicholas JM, et al. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial. Lancet Neurol. 2017;16(8):591–600. doi: 10.1016/S1474-4422(17)30113-8
   PubMed Web of Science ®Google Scholar
• Confavreux C, Saddier P, Grimaud J, et al. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology. 1996;46(6):1607–1612. doi:10.1212/WNL.46.6.1607
   PubMed Web of Science ®Google Scholar
• Correale J. BTK inhibitors as potential therapies for multiple sclerosis. Lancet Neurol. 2021;20(9):689–691. doi:10.1016/S1474-4422(21)00250-7
   PubMed Web of Science ®Google Scholar
• Schneider R, Oh J. Bruton’s tyrosine kinase inhibition in multiple sclerosis. Curr Neurol Neurosci Rep. 2022;22(11):721–734. doi:10.1007/s11910-022-01229-z
   PubMed Web of Science ®Google Scholar